S 1882 · 112th Congress 2011–2013, ended

FAIR Generics Act

Latest action · Nov 16, 2011 Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text of measure as introduced: CR S7616-7617)

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedNov 16, 2011
  2. Passed SenateNot reached
  3. Passed HouseNot reached
  4. To the PresidentNot reached
  5. Became lawNot reached

Summary

Fair And Immediate Release of Generic Drugs Act or the FAIR Generics Act - Amends the Federal Food, Drug, and Cosmetic Act (FFDCA) to revise the definition of “first applicant” for purposes of the 180-day exclusivity period given to first applicants to file an abbreviated new drug application (generic drug). Makes applicants for a generic drug eligible for the exclusivity period only if they have not entered into a disqualifying agreement (an agreement between a generic drug applicant and the holder of the application for the listed drug [brand name drug] or the patentholder for the brand name drug whereby the generic drug applicant agrees not to seek approval of its generic drug or not to begin the commercial marketing of its generic drug until the expiration of the exclusivity period awarded to another generic applicant).

Expands the definition of “first applicant” to include an applicant that meets the following criteria: (1) the applicant is not the first generic applicant; (2) either no action for patent infringement was brought, such action was withdrawn or dismissed by a court without a decision that the patent was valid and infringed, or the court decided that the patent was invalid or not infringed; and (3) the applicant does not begin commercial marketing of such drug until 30 days after the first applicant began such commercial marketing.

Prohibits a party that enters an agreement to delay seeking approval of its generic drug application or to delay the commercial marketing of a generic drug from seeking approval of its application or beginning commercial marketing before the earlier of: (1) the latest date set forth in the agreement to seek approval or market the drug without regard to any earlier date under the agreement when commercial marketing could begin, or (2) 180 days after another first applicant begins commercial marketing of such drug.

Requires notice to the Secretary of the Health and Human Services (HHS) of the details of any agreement under this Act not later than ten business days after execution of the agreement.

Declares that the exclusive remedy for an infringement of a patent included within a new drug application shall be an action brought under the FFDCA within the 45-day period prescribed.

Cosponsors 12

Members who signed on, in the order they did. Signatures ran from Nov 16, 2011 to Sep 10, 2012; 3 are original cosponsors, there from the day it was introduced.

SeatCosponsorSigned on
R-LADavid VitterOriginalNov 16, 2011
D-ORJeff MerkleyOriginalNov 16, 2011
D-OHSherrod BrownOriginalNov 16, 2011
I-VTBernard SandersNov 17, 2011
D-MNAl FrankenDec 7, 2011
D-MNAmy KlobucharJan 30, 2012
D-WIHerb KohlFeb 6, 2012
D-NMTom UdallMay 9, 2012
D-NHJeanne ShaheenMay 14, 2012
D-SDTim JohnsonMay 14, 2012
D-ILRichard J. DurbinJun 21, 2012
D-VAJim WebbSep 10, 2012

Committees 1

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
SenateHealth, Education, Labor, and Pensions Committee
Referred Nov 16, 2011

Actions 3

Everything that happened, newest first.

  1. Nov 16, 2011Introduced in Senate
  2. Nov 16, 2011Sponsor introductory remarks on measure. (CR S7616)
  3. Nov 16, 2011Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (text of measure as introduced: CR S7616-7617)

In the Congressional Record 1

Days the Record’s own index lists this bill, newest first, with the pages and the members it names. Pages starting H are the House, S the Senate, E Extensions of Remarks.

WhereIn the RecordMembersDate
SenateDebate and remarks S7616Text printed S7616Jeff Bingaman D-NM (text)Nov 16, 2011

Titles 3

Every title it has carried, official and short, at each stage.

Official Title as Introduced
A bill to amend the Federal Food, Drug, and Cosmetic Act to ensure that valid generic drugs may enter the market.
Short Titles as Introduced
FAIR Generics Act
Fair And Immediate Release of Generic Drugs Act

Subjects

Assigned by the Library of Congress. Policy area: Health.

Text 1

Each version as it was printed, newest first.

  1. Nov 16, 2011Introduced in Senate

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details. Other amounts

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.